ABCDx, a spin-off company from the University of Geneva and VIHR of Barcelona has developed the first diagnostic tool to detect traumatic brain injuries. The first product TBICheck(TM) is now available and CE marked. Additional products are in the pipeline in the detection of stroke origin, allowing earlier patient treatment and better outcomes.
A Norwegian medical technology company going global, with offices in Oslo, Aalesund, Munich and Toronto. Ably aims to be the preventive healthcare company, shifting the focus from treatment to prevention. By moving society towards preventive healthcare, we can avoid many of the healthcare issues facing society today. We find it essential to involve health personnel in the development process from the very beginning – codesigning future health solutions every step of the way. The first product developed by Ably is the Ably bed, a smart patient bed that will reduce nurse burden, pressure injuries and falls, all the while mobilizing the patient. The hospital bed, traditionally seen as something that inhibits mobility, has been redefined with the Ably bed, the design of which has been inspired by the human spine. The company consists of individuals with expertise in a broad range of subjects relevant to healthcare – industrial design, engineering, health economics and quality assurance. Combined, this expertise allows us to seek out disruptive solutions to longstanding healthcare problems.
Start-up and worldwide first company to build and certify a tactile, robotized, contactless laser osteotome - CARLO® (Cold Ablation Robot-guided Laser Osteotome) - using AI for laser control, providing a developer tool box for the CARLO® community to program indication- and process specific Apps for osteotomies thruout the body. CARLO® is enabling a complete digital workflow from pre-operative planning, to a mechanically and contact free osteotomy, to a post-op feed-back loop to improve the pre-operative planning. The osteotomies are patient specific, freely shaped, open porous bone cuts for quicker patient recovery.
Priv.-Doz. Dr. med. Bernhard Kreymann, nephrologist and founder of ADVITOS GmbH (previously Hepa Wash GmbH), has been working on the topic of liver and multi-organ support since 1994. During his time at the Munich University Hospital Rechts der Isar, he invented single-pass albumin dialysis in 1995, which is still used today to stabilize patients until liver transplantation. However, the method is not effective or inexpensive enough to be used more widely in everyday clinical practice.
Due to the high financial requirements, further development of a single pass albumin dialysis could not be done at the university. As a result, Hepa Wash was founded as a one-man start-up in a research lab in Garching near Munich in mid-2005. The development of the company was made possible over the years by means of several financing rounds by private investors, KfW banking groups and employees. The idea was to implement effective liver support therapy from concept to marketing. Not only has that goal been achieved, but today’s ADVOS procedure is suitable both for hepatic dialysis and is the first method in the world for extended and individualized support of the main detoxification organs: the liver, lungs and kidneys.
Aiforia Technologies is a medical AI software company in a scale up phase. We have a unique approach in bringing deep learning AI to the hands of pathologists and other medical professionals in image analysis, enabling them to scale up development of new AI models to automate any image analysis task, rapidly and cost effectively. As a result, patients will have faster, more accurate diagnosis and more personalized care.
Aiforia® Cloud is used today in medical research and drug development applications around the world, including big pharma companies, contract research organizations and leading medical research institutes. In order to accelerate the market entry to clinical diagnostics and to ramp up the business, we are preparing for the next round of financing (round B) and looking for investors to join our ambition.
BAYOOMED is specialized in the development of medical apps and medical software. With more than 250 person years of project experience, BAYOOMED is highly professional in the regulated CE & FDA environment. We support more than 800 medical and pharma companies and are among the most experienced medical software developers in Europe.
We engineer MHEALTH / EHEALTH applications under iOS (iPhone & iPad) and Android according to IEC 62304 and support product developers and innovators from the pharmaceutical and medical technology sectors in all phases of software product lifecycle. Our Quality management processes certified by TÜV Hessen according to ISO 13485 are a testament to our passion for sustainable solutions and distinct customer focus.
A clinical stage, venture-backed, company developing a non-invasive, self-calibrating intracranial pressure measurement device. The company is headquartered in Boston with ISO-13485-certified operations in Kaunas, Lithuania. The platform is designed around the use of image-guided Doppler-ultrasound and is intended to assist in the detection and management of altered intracranial dynamics for neurological applications including head trauma, hydrocephalus, stroke, pseudotumor cerebri and brain tumors, and in certain forms of glaucoma where visual loss has been correlated with the gradient between intraocular and intracranial pressures. Clinical results in previous versions of the instrument have demonstrated accuracy, precision and sensitivity comparable to those obtained from invasive ICP monitoring systems and sensors requiring surgical implantation and taken as the gold standard.
The Company is now conducting clinical validation trials in three institutions in the US and in Europe in anticipation of an FDA submission. Application for renewal of an existing CE mark has been submitted.
The Company has nine employees, a robust patent estate, an exceptional international scientific advisory board, and top rated legal, intellectual property, statistical and regulatory advisors.
An industry leader in the field of Transcranial Magnetic Stimulation (TMS). The company is devoted to the development of a better solution for the treatment of brain disorders. BrainsWay’s flagship Deep TMS technology is a non-invasive, well-tolerated outpatient treatment, clinically proven to treat psychiatric and neurological conditions. BrainsWay has received FDA-clearance for both major depression (MDD) and obsessive compulsive disorder (OCD- De Novo) and is developing more applications outside of the US. The company also has approval in Japan and other Asian countries. BrainsWay continues to push the TMS envelope with multiple clinical studies and further research into novel indications.
BrainsWay has an experienced business and development management team, as well as the backing of key scientific opinion leaders. BrainsWay was founded in 2003 and began trading on the NASDAQ in 2019 under the symbol BWAY.
EMFIT develops and manufactures IoT sensor solutions using its proprietary sensor technology based on electro-active ferroelectret film. The current product portfolio consists of products for sleep and recovery analysis, sleep apnea scoring and seizure monitoring, which are in everyday use in over 100 000 beds, in hospitals, nursing homes and private homes. Emfit was founded in 1990. Company employes 20 people, in Finland, Germany, USA and China. During its long existence, it has always focused on the same material technology and developed applications it has spun off. For the last 10 years, it has solely focused on digital health care. It designs, develops and manufactures its products with own team. The company team consists of 20 highly motivated, skilled and experienced professionals with years of top-level experience in launching and selling new products to the global healthcare market. In total, the team members have participated in the development, regulatory clearance and roll-out of nearly ten medical devices, including success stories like EMFIT MM tonic-clonic seizure monitor and EMFIT DVM discreet vitals monitor. AI and machine learning technologies are in daily use.
Emperra offers a unique, holistic, state of the art, proven and AI enabled Diabetes Management solution to help the society to handle a pandemic disease and burden: Diabetes. Therefore Emperra owns the complete value chain: We generate data via our proprietary Hardware, transfer the data end-to end encrypted into the cloud, process them with algorithms and send the core learnings and predictions back to the patient and doctors. In parallel the system is brand agnostic, open for third party devices, algorithms & solutions, certified as medical product (Hardware & Software) and so far, the best tested and commercially available system in the market.
GlucoSet aims to make glucose control in ICUs possible, to reduce mortality, complications and costs. Blood glucose levels are elevated and unstable in hospital intensive care unit (ICU) patients. This leads to costly infections, increased length of stay and mortality. The GlucoSet intravascular sensor delivers continuous and accurate information on patient's blood glucose level, enabling normalization of glucose levels, without the risk of sudden and dangerously low glucose levels.
LATTICE MEDICAL proposes a new resorbable breast implant: MATTISSE, a class 3 implantable medical device, which allows regeneration of damaged tissues in a natural, personalized way and in a single surgery. This regeneration is done thanks to the use of autologous fat tissues (adipose tissue), which, positioned inside the implant will regenerate over a period of 8 months and at the same time the prosthesis will disappear completely from the body.
The implant is made of bioabsorbable polymer and manufactured thanks to 3D printing and could be custom-made.
MedAware is transforming patient safety by leveraging AI for the early identification and prevention of medication errors, evolving adverse events, opioid abuse, and other medication related risks. Medaware's flagship product is the first in a suite of decision support solutions that transform real physician practice data into actionable knowledge for the payer, provider, and consumer markets.
We Radically Simplify the Integration of PGHD into Clinical Systems. In a highly-regulated and fragmented industry, the integration of Patient-Generated Health Data (PGHD) into clinical systems remains a major challenge for healthcare providers, pharmaceutical companies and Clinical Research Organizations (CROs). In order to better cope with the rise of chronic conditions and an aging population, Medisanté makes it easy - anywhere in the world - for care teams, bio-medical engineers, and patients at the same time. Easy always wins!
We Leverage Global Tech to Scale Remote Patient Monitoring Once the care teams have assigned a medical IoT device in their clinical system, they don’t need to unveil the patient’s identity to any device manufacturer. In order to scale Remote Patient Monitoring, Medisanté delivers a global medical IoT infrastructure that eliminates the need for any Bluetooth or Wi-Fi configuration. It combines the best of global tech for anonymous device data with the best of healthcare compliance and privacy for sensitive patient data.
A Global Direct-to-Cloud Medical IoT Solution Medisanté delivers a zero-touch medical IoT infrastructure that uniquely leverages global tech to put IoT to work for care teams anywhere in the world. It helps healthcare providers, pharmaceutical companies and CRO capture PGHD for their clinical systems without the hassle of Bluetooth or Wi-Fi, and without unveiling the identity of their patients to any device vendor. Medisanté empowers connected care by expanding the expertise of care teams beyond the four walls of their hospital or practice. https://medisante.ch/
MedVest UK LLP
Medvest is a digital health & medical device accelerator investing in Israeli medtech startups & taking them through the acceleration process to commercialisation. Highly experienced team with a strong execution & exit track record. Medvest has built an ecosystem to facilitate this acceleration for the portfolio companies. Medvest has offices in London, UK, Hannover, Germany & Tel Aviv, Israel. It will soon have a China based office as well.
The TrackCath system, a patented sensing technology, measures blood flow velocity. Applied to TrackCath access catheter, the technology identifies small blood vessel orifices for cannulation purposes. The TrackCath system aims to replace X-ray and contrast media during minimally invasive cardiovascular procedures, for improved patient safety. TrackCath met primary and secondary endpoint in a 40-patient multi-center first in human clinical trial in Germany. Commercialization will begin in Q4-19 in top EVAR centers in WE. Medyria has a sustainable business model, made of a disposable 8 French sensor guided Catheter, cost neutral for the hospital and a Flow Monitoring Unit & monitor on consignment (No Capex for the hospital).
Blood flow velocity sensing technology applied to catheters serves as a platform to address an array of potential applications in the human vascular system. Our strategy is to focus on EVAR applications first, then expand into the larger Aortic and Coronary markets.
An Israeli digital health medical device startup, developed a novel, cost-effective, wireless ingestible capsule system for the treatment of Obesity and Overweight. The company have already launched First in Human Safety clinical study in Israel Hospital, and its first phase has been already completed with no serious adverse events. The company IP includes 2 granted patents,4 pending applications, and additional patents in the drafting. The Weight management market has a Huge volume: $250B annually. Melcap brings to the market First truly affordable, AI-based weight loss system. It has patented, combined therapy and behavioral psychology approach, which finally help to Prevent Obesity. Melcap system could be used both by Overweight and Obese Individuals. Currently, 1.5 billion overweight adults do not have a treatment solution. Melcap suggests to the overweight individuals an affordable solution which will give them the possibility to not cross the line of BMI 35 and prevent Obesity. Melcap developed two systems: Appetite Reduction System(ARS) and Weight Reduction System (WRS). Both systems have the same technological basics, yet differs in the type of Mobile App. The ARS version efficacy study is planned on the Q4 of 2019, and sales in Israel will be launched in the Q2 2020. The company will apply to the CE mark approval and run efficacy study for the WRS version in 2020. The CE mark approval is expected at the Q2 2021 and for FDA at Q2 20. Melcap business model is based on a reusable kit and en-mass disposable capsules sales. An additional source of the revenue is Annual / Monthly Subscriptions for Mobile App. The unit economics shows high Gross margin around 80% at the 10 dollars’ price of the capsule at cost 2 dollars and 75 dollars price for the wearable at the cost of 15 dollars.
A groundbreaking data science company based in Gent (BE) and Cambridge (US) that builds linked data ecosystems using knowledge graphs over silo-ed internal and external data. The open plugin-architecture includes (1) an award-winning semantic search interface, (2) powerful visual analytics, (3) an ultra-scalable data ingestion, data linking, data curation engine boosted by (4) AI plugins to do magic with highly curated, high quality data. Integrating, harmonizing, and mining continuous growing amounts of complex data becomes simple. ONTOFORCE always delivers a working solution in days, not months or years, and quickly helps your company (1) to be more efficient, (2) to squeezes time moving products faster to market and (3) helps fail early and improve probability of success by unlocking insights from known but also hidden or difficult to access data. With ONTOFORCE's platform, DISQOVER, your data unified, linked and more intelligent data is ready for instant action. Decision-makers choose more wisely, researchers accelerate their research, experts get more accurate recommendations, and individuals understand situations better. Making meaning and bringing simplicity to data complexity is our core business. We provide citizen data science power to everyone helping them find insights beyond imagination to impact everyone's life, from healing patients to moving drugs faster to market.
The company has raised 11M EU, has doubled its employees from 20 to 40 in 2019, is tripling ARR every year and has not only blue-chip multinational customers (BMS, Amgen, AstraZeneca ...) but also great partnerships (Harvard, Stanford, IMEC, VIB, UCSD ...) The company wins a lot of tech (Gartner Cool Vendor, BIO IT Best of Show) and business awards (2018 EU Startup winner, 2019 Scale Up of the year ...) in is at the verge of breaking through internationally ready for a round B in H1 2010 to scale even faster.
Pixium Vision is creating a world of bionic vision for those who have lost their sight, enabling them to regain visual perception and greater autonomy. Pixium Vision’s bionic vision systems are associated with a surgical intervention and a rehabilitation period. Prima System sub-retinal miniature photovoltaic wireless implant is in clinical testing for patients who have lost their sight due to outer retinal degeneration, initially for atrophic dry age-related macular degeneration (dry AMD). Pixium Vision collaborates closely with academic and research partners, including some of the most prestigious vision research institutions in the world, such as: Stanford University in California, Institut de la Vision in Paris, Moorfields Eye Hospital in London, Institute of Ocular Microsurgery (IMO) in Barcelona, University hospital in Bonn, and UPMC in Pittsburgh, PA. The company is EN ISO 13485 certi fied and qualifies as “Entreprise Innovante” by Bpifrance. https://www.pixium-vision.com/en
Resistell proposes an alternative to culture based antibiogram, the current gold standard in antibiotic susceptibility testing. Our offering is a diagnostic device. The rapid AST method is based on the detection of movement caused by living bacterial cells. Because the test is growth independent rapid AST, we reduce the time taken to get a result from days to minutes. Resistell provides information on which antibiotic should be used to treat the patient, and the concentration at which it should be administered.
Respinova has developed a new device for the treatment of COPD. COPD is a group of progressive, debilitating respiratory conditions that has become the third leading cause of death. For the last 50 years, there have been no substantial advances in therapy. Treatment for COPD is primarily by inhaled bronchodilators. However, these drugs only target the upper airways. Most of COPD is caused by the collapse of small airways. Respinova’s Pulsehaler™ technology is the first and only treatment to directly open the small airways, thereby reducing breathlessness and improving patient’s exercise capacity.
A biotechnology company which provides a unique point-of -care device used by doctors to offering a game changing approach to improving the breadth of pathogen detection. It's pathogen identification testing approach uses a process called Micro Organism Quantitative Spectroscopy (MOQS) to provide a more sensitive and comprehensive approach to the identification of pathogens enabling targeted antimicrobial therapy and improved antibiotic stewardship.
Rsquared technology and extensive database of pathogens genomic information enables clinicians and biopharma companies to overcome some of the current limitation of infectious agent detection.
Surge-on Medical has developed the next generation of minimally invasive surgical instruments. We are setting new standards to deliver better healthcare. Through cable-free technologies, we have created freedimensional instruments that provide better access to surgical areas and replace current pre-bent instrumentation. Surge-on Medical has been granted four international patents which make minimally invasive instruments steerable, detachable and cleanable.
Surgical operations involving bone cutting always carry risk and often lead to soft tissue injuries. Most devastating complications are related to operations in the head, neck and spine areas. Millions of such operations are performed every year and various clinical studies indicate that the risk of soft tissue injury can be over 10%. Surgify technology improves the safety, speed and precision of bone surgery to minimize these risks.
A Venture Capital backed privately held company focused on the development and commercialization of tools for use in the focal ablation of soft tissues. The company was founded in 2006 with initial in-vivo studies undertaken during 2007 and first in man studies were completed in 2010. Trod Medical obtained a 510K clearance from the FDA in 2008 and a CE mark for its Encage™ Focal Ablation Device in 2015.
The expertise of UGA Biopharma is the development of biologics and biosimilars. This high speed contract development involves all the necessary steps from cell line development and bioprocess development to the development of purification processes and analytics. Furthermore, First CHOice® high-performance cell culture media and feeds are supplied in order to optimize the quality and product concentration of biologics and biosimilars. In addition, UGA Biopharma offers to customers ready-to-use biosimilar cell lines. The company supplies its customers in Germany and abroad from its headquarters in Hennigsdorf and already has several clients with UGA products in clinical trials or who have already received a market approval.
By developing a single set of novel, proprietary reagents used both for biomarker discovery (higher content, low throughput) and translational use (lower content, high throughput), Ultivue is connecting the insights gained from research directly into the pathology lab. Ultivue’s UltiMapper™ multiplexed assays applied to tissue biopsy samples enable simultaneous quantitation of multiple biomarkers with sub-cellular spatial resolution and fit completely within traditional IHC workflows. Translational and clinical researchers leverage UltiMapper assays to elucidate complex biology and demonstrate their clinical utility as precision medicine research tools. Ultivue is expanding its UltiMapper assay product portfolio and menu of contract research services to provide a comprehensive set of precision medicine solutions for oncology research and focus in other therapeutic areas.
Vivior offers an innovative service for all customers and patients that require a solution to improve their vision. Our objective behavioral data supports experts like ophthalmic surgeons, optometrists, opticians and others to offer personalized solutions to their customers and patients. The speci c solution - be it an intraocular lens for cataract patients, laser eye surgery or progressive spectacle lenses - will be customized to the customer's and patient's lifestyle and visual needs.
A clinical stage medical device company developing a genuinely new generation of Neuromonitoring and Neuromodulation electrodes by means of its proprietary SCBI technology. WISE’s electrodes are highly ergonomic, conformable, soft and thin, thus allowing great adhesion, minimal invasiveness and excellent adaptability on neural tissues. Currently, WISE is clinically validating its WCS electrodes for electrophysiological brain monitoring and completing the development of the WISE EXPERT lead, the first Multi-column SCS Paddle lead that can be implanted percutaneously by a Pain Therapist.
A medical device company that designs specialized orthopedic solutions for the aging population. Our premiere product is the OGmend™ system, a bio-textile device that helps enhance fixation in surgical procedures that use orthopedic screws. It is the first solution to provide a simple, repeatable, and standardized solution for orthopedic surgeons and is especially useful in relieving the challenge of achieving fixation in compromised bone.
Our initial target market includes the 4.5 million trauma and spine procedures performed annually on patients who suffer from compromised bone as a result of conditions such as osteoporosis, diabetes, smoking, Parkinson’s, chemotherapy treatment, etc. (a $2.3B market opportunity). We have completed bench, animal, and clinical studies to date and own more than 28 patents covering our technology. Woven received a CE mark and began initial commercial activity in Europe.